What is Haemonetics's total equity?

Haemonetics (HAE) reported total equity of $796.32M in Q1 2026.

How has Haemonetics's total equity changed year-over-year?

Haemonetics's total equity decreased by 3.0% year-over-year, from $820.84M to $796.32M.

What is the long-term trend for Haemonetics's total equity?

Over 5 years (2021 to 2026), Haemonetics's total equity has grown at a 1.7% compound annual growth rate (CAGR), from $731.67M to $796.32M.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Haemonetics HAE Total Equity

Total Equity at other companies

AbbottABT

$52.06B+6.7%

TFX

TeleflexTFX

$3.08B-24.7%

Boston ScientificBSX

$25.86B+16.4%

MedtronicMDT

$49.46B+3.0%

LivaNovaLIVN

$1.21B+17.1%

ICU MedicalICUI

$2.11B+6.3%

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.37B-18.0%

Enterprise value$4.4B-12.5%

P/S2.5×-0.5×

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's total equity?: Haemonetics (HAE) reported total equity of $796.32M in Q1 2026.
How has Haemonetics's total equity changed year-over-year?: Haemonetics's total equity decreased by 3.0% year-over-year, from $820.84M to $796.32M.
What is the long-term trend for Haemonetics's total equity?: Over 5 years (2021 to 2026), Haemonetics's total equity has grown at a 1.7% compound annual growth rate (CAGR), from $731.67M to $796.32M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.